• Merck and UAB Recruiting 16 to 26 Year Old Mothers Who Just Gave Birth to Enroll in Gardasil 9 Vaccine Trials

    The University of Alabama at Birmingham (UAB) in collaboration with Merck pharmaceutical company is planning to conduct Gardasil 9 vaccine trials on postpartum mothers between the ages of 16 to 26 immediately after giving birth at the UAB hospital. According to ClinicalTrials.gov, the desired outcome of this study is to have more young women vaccinated with the Gardasil vaccine, because they do not believe enough young women are being vaccinated: "Due to low HPV vaccine uptake in the US, innovative approaches to vaccinating vulnerable populations are necessary in order to maximize the cancer prevention potential of this vaccine." Previous studies on the Gardasil vaccine have shown that young women who are in the hospital due to giving birth are open to receiving the Gardasil vaccine, particularly Hispanic populations: "The puerperium is a time period when women are engaged in the healthcare system and have almost universal access to affordable health care. Two prior studies have shown that postpartum HPV vaccination is acceptable to patients, and high rates of vaccination were achieved in these primarily Hispanic populations." Merck and UAB want to test the vaccine on 16 to 26 year old postpartum mothers because "the immune response in young women is less robust than in adolescents," and because "no studies have examined immunogenicity in postpartum women specifically." Therefore, 16 to 26 year old young mothers who have just given birth at the UAB hospital will become test subjects of the Gardasil 9 vaccine. Will these young mothers in Alabama have sufficient information to make the decision to participate in these Gardasil vaccine trials just after giving birth? Will they understand the potential risks for harm, which includes heart disease (POTS), premature menopause (“Primary Ovarian Failure”) and a whole list of autoimmune disorders that have been hidden from the public but revealed by a 2017 study done in Mexico?

    Read full story...

  • Merck and UAB Recruiting 16 to 26 Year Old Mothers Who Just Gave Birth to Enroll in Gardasil 9 Vaccine Trials

    On 7th March I sent a message to the contact person of the clinical trial number 03451071, Ms Sarah Dilley asking if there will also be testing of the newborn babies regarding potential side effects due to possible excretion of the vaccine into breastmilk.

    I also sent a message on 7th March to the contact person Eugene Shapiro regarding trial number 02994290 which was titled:
    Evaluation of the Implementation and Effectiveness of a Pilot Quality Improvement Program to Increase HPV Vaccine Uptake: Inpatient Postpartum HPV Immunization (IPP-HPV) Program.

    Quote from the Detailed Description; "... the HPV vaccine, which is safe in breastfeeding women"
    My question was "Are there studies which confirm the safety in breastfeeding women?"

    It is a week ago since I sent the two messages and I have not yet received answers from either.





  • Merck and UAB Recruiting 16 to 26 Year Old Mothers Who Just Gave Birth to Enroll in Gardasil 9 Vaccine Trials

    So they (Merck and University of Alabama) are willing to risk not only the young women lives, but also orphaning the new-born babies, just to promote that murderous vaccine agenda???


  • Merck and UAB Recruiting 16 to 26 Year Old Mothers Who Just Gave Birth to Enroll in Gardasil 9 Vaccine Trials

    According to section 8.3 of the original quadrivalent Gardasil vaccine package insert, infants of breastfeeding mothers in the prelicensure trials were nearly TWICE as likely to have a serious adverse event if their mother had received Gardasil over the aluminum adjuvant "placebo."

    8.3 "It is not known whether GARDASIL is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when GARDASIL is administered to a nursing woman.

    GARDASIL or AAHS control were given to a total of 1133 women (vaccine N = 582, AAHS control N = 551) during the relevant Phase 3 clinical studies.

    Overall, 27 and 13 infants of women who received GARDASIL or AAHS control, respectively (representing 4.6% and 2.4% of the total number of women who were breast-feeding during the period in which they received GARDASIL or AAHS control, respectively), experienced a serious adverse reaction.

    In a post-hoc analysis of clinical studies, a higher number of breast-feeding infants (n = 7) whose mothers received GARDASIL had acute respiratory illnesses within 30 days post vaccination of the mother as compared to infants (n = 2) whose mothers received AAHS control."


    So we already know the answer.

    I assume that's why section 8.3 doesn't exist in the package insert for Gardasil 9.







  • Merck and UAB Recruiting 16 to 26 Year Old Mothers Who Just Gave Birth to Enroll in Gardasil 9 Vaccine Trials

    Admin said:

    The University of Alabama at Birmingham (UAB) in collaboration with Merck pharmaceutical company is planning to conduct Gardasil 9 vaccine trials on postpartum mothers between the ages of 16 to 26 immediately after giving birth at the UAB hospital. According to ClinicalTrials.gov, the desired outcome of this study is to have more young women vaccinated with the Gardasil vaccine, because they do not believe enough young women are being vaccinated: "Due to low HPV vaccine uptake in the US, innovative approaches to vaccinating vulnerable populations are necessary in order to maximize the cancer prevention potential of this vaccine." Previous studies on the Gardasil vaccine have shown that young women who are in the hospital due to giving birth are open to receiving the Gardasil vaccine, particularly Hispanic populations: "The puerperium is a time period when women are engaged in the healthcare system and have almost universal access to affordable health care. Two prior studies have shown that postpartum HPV vaccination is acceptable to patients, and high rates of vaccination were achieved in these primarily Hispanic populations." Merck and UAB want to test the vaccine on 16 to 26 year old postpartum mothers because "the immune response in young women is less robust than in adolescents," and because "no studies have examined immunogenicity in postpartum women specifically." Therefore, 16 to 26 year old young mothers who have just given birth at the UAB hospital will become test subjects of the Gardasil 9 vaccine. Will these young mothers in Alabama have sufficient information to make the decision to participate in these Gardasil vaccine trials just after giving birth? Will they understand the potential risks for harm, which includes heart disease (POTS), premature menopause (“Primary Ovarian Failure”) and a whole list of autoimmune disorders that have been hidden from the public but revealed by a 2017 study done in Mexico?

    I share your questions. I also wonder why they are choosing to give THREE doses of Gardasil 9 instead to the two-dose regimen recommended by the CDC.

    I also wonder if they will do any diagnostic testing prior to the study to ascertain previous HPV infection and immune status, and if previously undiagnosed autoimmunity, immune suppression or HPV infection will be included as exclusion criteria. Will they only administer these vaccines if they are absolutely certain that the woman has not already previously received the HPV vaccine? What criteria will determine the accuracy of HPV vaccine status?

    When will the women be approached about the study? At the first prenatal visit or at some point in the pregnancy? Will they be given ample opportunity and ample information about the study to make an informed and rational decision as to whether or not they want to participate in the study?

    Have any studies been shown that ensure the safety to the infant of being exposed to the Aluminum in TDaP, Rhogam(when indicated) and HPV 9 vaccine? Have the study authors and Merck considered safety issues for the infant?

    How important is it to examine immunogenicity in postpartum women specifically?

    Is this study a thinly veiled attempt to bolster the marketing efforts for a vaccine which is increasingly being rejected?

  • Merck and UAB Recruiting 16 to 26 Year Old Mothers Who Just Gave Birth to Enroll in Gardasil 9 Vaccine Trials

    Quoted from Gardasil package insert. There is reason to believe that Gardasil 9 will be even more dangerous for the babies:

    8.3 Nursing Mothers
    Women 16 Through 45 Years of Age
    It is not known whether GARDASIL is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when GARDASIL is administered to a nursing woman.

    GARDASIL or AAHS control were given to a total of 1133 women (vaccine N = 582, AAHS control N =551) during the relevant Phase 3 clinical studies.

    Overall, 27 and 13 infants of women who received GARDASIL or AAHS control, respectively (representing 4.6% and 2.4% of the total number of women who were breast-feeding during the period in which they received GARDASIL or AAHS control, respectively), experienced a serious adverse reaction.

    In a post-hoc analysis of clinical studies, a higher number of breast-feeding infants (n = 7) whose mothers received GARDASIL had acute respiratory illnesses within 30 days post vaccination of the mother as compared to infants (n = 2) whose mothers received AAHS control.

  • Merck and UAB Recruiting 16 to 26 Year Old Mothers Who Just Gave Birth to Enroll in Gardasil 9 Vaccine Trials

    Vaccination is medical experimentation.

    Gardasil has been known to cause sterility, so what better group to experiment on than women who've already had a child.

    Read the Gardasil package insert: https://www.fda.gov/downloads/BiologicsBloodVaccin...

  • Merck and UAB Recruiting 16 to 26 Year Old Mothers Who Just Gave Birth to Enroll in Gardasil 9 Vaccine Trials

    Admin said:

    The University of Alabama at Birmingham (UAB) in collaboration with Merck pharmaceutical company is planning to conduct Gardasil 9 vaccine trials on postpartum mothers between the ages of 16 to 26 immediately after giving birth at the UAB hospital. According to ClinicalTrials.gov, the desired outcome of this study is to have more young women vaccinated with the Gardasil vaccine, because they do not believe enough young women are being vaccinated: "Due to low HPV vaccine uptake in the US, innovative approaches to vaccinating vulnerable populations are necessary in order to maximize the cancer prevention potential of this vaccine." Previous studies on the Gardasil vaccine have shown that young women who are in the hospital due to giving birth are open to receiving the Gardasil vaccine, particularly Hispanic populations: "The puerperium is a time period when women are engaged in the healthcare system and have almost universal access to affordable health care. Two prior studies have shown that postpartum HPV vaccination is acceptable to patients, and high rates of vaccination were achieved in these primarily Hispanic populations." Merck and UAB want to test the vaccine on 16 to 26 year old postpartum mothers because "the immune response in young women is less robust than in adolescents," and because "no studies have examined immunogenicity in postpartum women specifically." Therefore, 16 to 26 year old young mothers who have just given birth at the UAB hospital will become test subjects of the Gardasil 9 vaccine. Will these young mothers in Alabama have sufficient information to make the decision to participate in these Gardasil vaccine trials just after giving birth? Will they understand the potential risks for harm, which includes heart disease (POTS), premature menopause (“Primary Ovarian Failure”) and a whole list of autoimmune disorders that have been hidden from the public but revealed by a 2017 study done in Mexico?

    I have so many questions regarding this study, and plan to contact Sarah Dilley, MD.

    "The safety and scientific validity of this study is the responsiblity of the study sponsor and investigators."

    What are the consequences to Merck and the University of Alabama at Birmingham if the study proves to be unsafe and/or fails to prove itself scientifically valid?


    Is 6 months an adequate duration of follow-up considering the fact that ASIA can occur months or years after the Adjuvant js injected? In this case, large doses of Aluminum adjuvant.

    Why 3 doses of Gardasil 9, when the CDC recommends a two-dose regimen of Gardasil?


    Are there known implications of a newborn receiving Aluminum in the quantities in this vaccine? How much is transmitted through the breastmilk?

    Are there synergistic effects of prenatal Aluminum from TDaP and postnatal Gardasil 9 Aluminum to the infant?

    Are any considerations being made for the infant?

    Will + HPV status eliminate the woman from the trial?

    Will previous HPV vaccination eliminate the woman from the trial?

    What is the rate of increase in HPV-related cancers in the U.S.? What data exists to support this?

    What sub-types of HPV are associated with these HPV-associated cancers?

    Is the incidence of HPV-related cancers increased in those who were HPV + prior to vaccination?

    Will the study participants be adequately informed of the potential development of Autoimmune disorders, Cardiac disorders, such as POTS, and Premature Menopause?

    How will informed consent be documented? Will the informed consent be given with a witness present? Wil it be videotaped?

    Is this study actually a marketing tool by Merck to increase uptake of Gardasil vaccine in light of its decreasing acceptance by women throughout the world?